Frequently Asked Questions

Dolutegravir inhibits the integrase enzyme that HIV uses to insert its genetic material into CD4 cells. By blocking this process, the medication prevents viral replication and reduces viral load to undetectable levels.

No, Dolutegravir is not a cure for HIV. However, when taken consistently, it effectively suppresses viral replication, allowing people with HIV to live long, healthy lives with an undetectable viral load.

Common brand names include Tivicay (Gilead Sciences) and TAPIVIR (Taj Pharmaceuticals). Generic versions are also available from various manufacturers worldwide.

The standard dose for adults and adolescents weighing 40 kg or more is 50 mg once daily. Dose adjustments may be needed with certain drug interactions or in special populations.

Dolutegravir can be taken with or without food. However, certain foods and supplements can affect absorption, so it is best taken at the same time each day with consistent meal patterns.

Common side effects include insomnia, headache, nausea, diarrhea, fatigue, and dizziness. Most side effects are mild and often improve within the first few weeks of treatment.

Serious side effects are rare but can include severe allergic reactions, liver problems, and mood changes. Patients should report any unusual symptoms to their healthcare provider immediately.

Some patients may experience modest weight gain while taking Dolutegravir, particularly when combined with certain other antiretrovirals. Regular exercise and healthy diet can help manage weight.

Some patients report mood changes, depression, or anxiety. These effects are usually mild and manageable with proper support. Mental health screening is recommended at baseline and during treatment.

Yes, the WHO recommends Dolutegravir for pregnant women with appropriate counseling. It has been shown to be safe and effective for both mother and baby when used as prescribed.

Yes, no dose adjustment is needed for any degree of renal impairment, including severe kidney disease. Dolutegravir is safe in patients with eGFR <15 mL/min.

Dolutegravir can be used with caution in hepatic impairment. No dose adjustment is needed for mild to moderate impairment, but use with caution in severe hepatic disease.

St. John's Wort should be avoided as it significantly reduces Dolutegravir levels. Antacids, calcium supplements, and iron supplements should be taken 2 hours before or 6 hours after Dolutegravir.

Yes, rifampin reduces Dolutegravir levels. When used together, Dolutegravir dose should be increased to 50 mg twice daily to maintain therapeutic levels.

Some anticonvulsants (carbamazepine, phenytoin, phenobarbital) reduce Dolutegravir levels. Dose adjustment may be needed. Consult with a healthcare provider before combining these medications.

Yes, Dolutegravir increases metformin levels. Metformin dose may need adjustment when used with Dolutegravir. Regular monitoring of renal function is recommended.

Proton pump inhibitors may reduce Dolutegravir absorption. If used together, monitor viral load carefully. H2 receptor antagonists are a better alternative if acid reduction is needed.

Dolutegravir typically shows rapid viral suppression. Most patients achieve undetectable viral load within 8-12 weeks of starting treatment, though individual responses may vary.

An undetectable viral load means HIV RNA levels are below 50 copies/mL (or the detection limit of the test). This indicates effective viral suppression and means the person cannot transmit HIV sexually (U=U).

Yes, Dolutegravir has a high barrier to resistance. Multiple mutations are required for resistance to develop, making it an excellent choice for both treatment-naive and treatment-experienced patients.

Yes, Dolutegravir is WHO-recommended as a preferred first-line treatment for all populations, including adults, adolescents, children, and pregnant women.

Yes, Dolutegravir is WHO-recommended as a preferred second-line treatment for patients failing first-line therapy, particularly those with resistance to other drug classes.

Cost varies by country and formulation. Generic versions are significantly cheaper than brand-name products. In many countries, Dolutegravir is available through government programs or NGOs at reduced cost.

Yes, generic Dolutegravir is available from multiple manufacturers worldwide, including Taj Pharmaceuticals. Generic versions are bioequivalent to brand-name products and significantly less expensive.

Store Dolutegravir at room temperature (20-25??C) away from light and moisture. Keep in original container. Do not store in bathrooms or near kitchen sinks due to humidity.

If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Never double-dose. Consistent adherence is important for treatment success.

No, Dolutegravir should not be stopped abruptly without medical guidance. Sudden discontinuation can lead to viral rebound. Any changes should be made under healthcare provider supervision.

Adherence is monitored through patient self-report, pill counts, pharmacy refill records, and viral load testing. Healthcare providers assess adherence at each visit and provide support as needed.

Poor adherence can lead to viral rebound, increased CD4 decline, and development of drug resistance. Healthcare providers can provide support, education, and resources to improve adherence.

Viral load should be checked at baseline, 4 weeks, 12 weeks, and then every 3-6 months after suppression is achieved. More frequent monitoring may be needed if adherence is a concern.

CD4 count should be checked at baseline and every 3-6 months during treatment. Once CD4 count recovers above 200 cells/mm??, monitoring frequency can be reduced.

CD4 count above 200 cells/mm?? is considered adequate for prevention of most opportunistic infections. Counts above 500 cells/mm?? indicate good immune recovery.

Yes, by suppressing viral replication and allowing CD4 count recovery, Dolutegravir helps prevent opportunistic infections. Prophylaxis may still be needed if CD4 count is very low.

Dolutegravir is effective against most HIV-1 subtypes. However, some rare subtypes or heavily treatment-experienced patients may have reduced susceptibility. Resistance testing can help determine suitability.

Dolutegravir has limited activity against HIV-2. Other antiretrovirals are preferred for HIV-2 infection. Resistance testing is important for HIV-2 patients.

TAPIVIR 50 contains 50 mg Dolutegravir for adults and adolescents. TAPIVIR DT 10 contains 10 mg Dolutegravir in dispersible tablets for pediatric patients with weight-based dosing.

TAPIVIR 50 tablets should not be crushed or split. TAPIVIR DT 10 dispersible tablets can be dispersed in water for easier administration to children.

Disperse the tablet in water or other liquid and drink immediately. Alternatively, swallow whole with water. Ensure the full dose is consumed.

Dolutegravir is present in breast milk. In resource-limited settings where formula feeding is not safe, breastfeeding is acceptable. In resource-rich settings, formula feeding is recommended.

No, current evidence does not show increased birth defects with Dolutegravir use during pregnancy. The WHO recommends it as a safe option for pregnant women.

Dolutegravir achieves viral suppression in over 85% of treatment-naive patients within 12 weeks. It is one of the most effective first-line antiretrovirals available.

Dolutegravir is highly effective in treatment-experienced patients, with suppression rates of 70-80% depending on resistance profile and adherence.

No, Dolutegravir must be used as part of a combination antiretroviral regimen with at least two other active drugs to prevent resistance development.

Common regimens include Dolutegravir + TDF/FTC, Dolutegravir + TAF/FTC, Dolutegravir + 3TC, and Dolutegravir + ABC/3TC. Specific regimens depend on patient factors and resistance profile.

Dolutegravir has superior efficacy and tolerability compared to earlier INSTIs like raltegravir and elvitegravir. It has a higher barrier to resistance and fewer drug interactions.

Dolutegravir has better efficacy, faster viral suppression, and a higher barrier to resistance compared to NNRTIs. It is preferred as first-line therapy over NNRTI-based regimens.

Dolutegravir has comparable efficacy to boosted protease inhibitors but with better tolerability, fewer side effects, and fewer drug interactions. It is preferred as first-line therapy.

Yes, Dolutegravir is increasingly used in resource-limited settings due to its efficacy, tolerability, and availability of affordable generic formulations.

Yes, Dolutegravir is on the WHO Essential Medicines List as a preferred first-line and second-line antiretroviral for HIV treatment.

The shelf life of Dolutegravir is typically 2-3 years from the date of manufacture when stored properly at room temperature away from light and moisture.

Yes, Dolutegravir can be used with tuberculosis treatment. When used with rifampin, Dolutegravir dose should be increased to 50 mg twice daily.

Yes, Dolutegravir can be used in hepatitis B coinfection. However, ensure the antiretroviral regimen includes agents active against hepatitis B (like TDF or TAF with 3TC or FTC).

Yes, Dolutegravir can be used in hepatitis C coinfection. Hepatitis C treatment can proceed independently. Monitor liver function regularly.

Dolutegravir does not significantly affect glucose metabolism. It is suitable for patients with diabetes. Regular glucose monitoring is still recommended.

Dolutegravir has minimal effect on lipid levels. It is preferred over some other antiretrovirals that may increase cholesterol and triglycerides.

Dolutegravir has minimal effect on bone density. It is preferred over some other antiretrovirals (like TDF) that may cause bone loss.

Yes, Dolutegravir can be used in patients with cardiovascular disease. It has minimal effect on lipid levels and is a good choice for this population.

Yes, Dolutegravir can be used in chronic kidney disease without dose adjustment. It is preferred over some other antiretrovirals that require dose adjustment.

Yes, Dolutegravir can be used in chronic liver disease with caution. Use with care in severe hepatic impairment. Monitor liver function regularly.

Dolutegravir has a high barrier to resistance. Resistance mutations are rare with good adherence. When resistance occurs, multiple mutations are usually required.

Common resistance mutations include R263K, H51Y, and G118R. However, these are rare with good adherence and are more common in treatment-experienced patients.

Dolutegravir resistance is difficult to reverse. Prevention through good adherence is key. Switching to alternative regimens may be needed if resistance develops.

Dolutegravir resistance is detected through genotypic resistance testing, which identifies specific mutations. Phenotypic testing can also be performed in specialized laboratories.

If resistance develops, work with your healthcare provider to switch to an alternative regimen based on resistance testing results. Adherence support is crucial.

Dolutegravir can be used in patients with alcohol use disorder. However, alcohol may worsen side effects like dizziness and insomnia. Counseling and support are recommended.

Dolutegravir can be used in patients with substance use disorder. Adherence support and treatment for substance use disorder are important for treatment success.

Yes, Dolutegravir can be used with methadone. No dose adjustment is needed for either medication. Monitor for any interactions or side effects.

Yes, Dolutegravir can be used with buprenorphine. No dose adjustment is needed. This combination is safe and effective for opioid-dependent patients with HIV.

Dolutegravir can be used in patients with depression. Some patients may experience mood changes, so mental health monitoring is important. Antidepressants can be used if needed.

Yes, Dolutegravir can be used in patients with anxiety. Some patients may experience anxiety as a side effect, which usually improves with time or can be managed with medication.

Most antidepressants can be safely used with Dolutegravir. However, some interactions are possible. Consult with a healthcare provider before combining medications.

Most anxiolytics can be safely used with Dolutegravir. However, benzodiazepines may increase CNS depression. Consult with a healthcare provider before combining medications.

Yes, Dolutegravir can be used in patients with hypertension. It does not significantly affect blood pressure. Antihypertensive medications can be used as needed.

Yes, Dolutegravir can be used in patients with diabetes. It has minimal effect on glucose metabolism. Regular glucose monitoring is still recommended.

No significant interaction between Dolutegravir and insulin. Insulin doses should be adjusted based on glucose monitoring as usual.

Dolutegravir may increase metformin levels. Other oral hypoglycemic agents generally do not have significant interactions. Monitor glucose levels regularly.

Yes, Dolutegravir can be used in patients with asthma. No significant interaction with asthma medications. Continue asthma management as usual.

Yes, Dolutegravir can be used in patients with COPD. No significant interaction with COPD medications. Continue respiratory management as usual.

Yes, Dolutegravir can be used in patients with active opportunistic infections. Start antiretroviral therapy promptly while treating the opportunistic infection.

Antiretroviral therapy should be started within 2 weeks of TB treatment initiation in most patients, or within 2 weeks in patients with CD4 <50 cells/mm??.

Yes, Dolutegravir can be used in patients with MAC. MAC prophylaxis should be continued until CD4 count recovers above 50 cells/mm??.

Yes, Dolutegravir can be used in patients with CMV. CMV treatment should proceed independently. Immune recovery with Dolutegravir helps prevent CMV progression.

Yes, Dolutegravir can be used in patients with PCP. PCP treatment should proceed independently. Immune recovery with Dolutegravir helps prevent PCP recurrence.

Yes, Dolutegravir can be used in patients with cryptococcal meningitis. Antifungal treatment should proceed independently. Immune recovery helps prevent relapse.

Dolutegravir is cost-effective due to its high efficacy, rapid viral suppression, and availability of affordable generic formulations. It reduces healthcare costs through fewer hospitalizations.

Most insurance plans cover Dolutegravir, especially generic versions. Coverage varies by plan and country. Check with your insurance provider for specific coverage details.

Yes, various organizations and manufacturers offer patient assistance programs to help patients access Dolutegravir at reduced cost or for free based on income.

Dolutegravir is an integrase inhibitor with superior efficacy and tolerability compared to earlier INSTIs. It has a higher barrier to resistance and fewer drug interactions.

Dolutegravir is expected to remain a cornerstone of HIV treatment. Long-acting formulations and combination pills are in development to improve convenience and adherence.

Yes, long-acting injectable formulations of Dolutegravir are in development and clinical trials. These may offer improved convenience and adherence for selected patients.

Dolutegravir is being studied for PrEP (pre-exposure prophylaxis) in HIV-negative individuals at high risk. However, it is not yet approved for this indication in most countries.

Dolutegravir plays a crucial role in HIV elimination efforts through its high efficacy, rapid viral suppression, and ability to achieve undetectable viral load (U=U), preventing transmission.

Dispose of Dolutegravir according to local regulations. Do not flush down the toilet or throw in trash. Ask your pharmacist about proper disposal methods or medication take-back programs.

Inform your healthcare provider about all medications, supplements, allergies, medical conditions, pregnancy plans, and any history of mental health issues or substance use.

Get baseline blood tests (CD4, viral load, liver and kidney function), ensure good understanding of medication regimen, establish adherence support, and discuss any concerns with your healthcare provider.

Expect possible side effects like insomnia or headache that usually improve within weeks. Viral load should decline rapidly. CD4 count recovery takes longer. Regular monitoring is important.

Dolutegravir is typically a lifelong treatment. It must be taken consistently to maintain viral suppression. Stopping treatment can lead to viral rebound and resistance development.

Stopping Dolutegravir is not recommended without medical supervision. Some research is exploring treatment interruption strategies, but this is not standard practice and carries significant risks.

With good adherence, Dolutegravir has a success rate of over 90% in achieving and maintaining undetectable viral load. Success rates are high in both treatment-naive and treatment-experienced patients.

Key factors include adherence, baseline CD4 count, viral load, resistance profile, presence of opportunistic infections, and overall health status. Adherence is the most important factor.

Use pill organizers, set phone reminders, take medication at the same time daily, use calendar or apps, involve family support, and discuss adherence challenges with your healthcare provider.

Resources include healthcare providers, HIV support groups, patient education materials, adherence counseling, mental health services, and community organizations dedicated to HIV care and support.

Yes, Dolutegravir is approved for children weighing 6 kg or more. Pediatric formulations like TAPIVIR DT 10 (dispersible tablets) are available with weight-based dosing.

Pediatric dosing is weight-based: 6-10 kg: 15 mg daily; 10-14 kg: 20 mg daily; 14-20 kg: 25 mg daily; 20-30 kg: 30 mg daily; >30 kg: 40 mg daily.